Canadian Pacific (CP) Upgraded By J.P. Morgan with $262.0 Target; Seres Therapeutics (MCRB) SI Increased By 0.42%

October 12, 2017 - By Winifred Garcia

Among 25 analysts covering Canadian Pacific (NYSE:CP), 17 have Buy rating, 0 Sell and 8 Hold. Therefore 68% are positive. Canadian Pacific has $225 highest and $119 lowest target. $175.94’s average target is 3.18% above currents $170.51 stock price. Canadian Pacific had 60 analyst reports since September 30, 2015 according to SRatingsIntel. As per Monday, October 24, the company rating was initiated by Seaport Global. CLSA initiated the shares of CP in report on Thursday, May 19 with “Underperform” rating. The rating was maintained by Cowen & Co with “Buy” on Friday, July 28. The stock of Canadian Pacific Railway Limited (USA) (NYSE:CP) has “Buy” rating given on Wednesday, June 28 by Stifel Nicolaus. The rating was maintained by Credit Suisse on Friday, February 19 with “Outperform”. The stock has “Hold” rating by Desjardins Securities on Thursday, April 21. Citigroup maintained the shares of CP in report on Friday, October 2 with “Buy” rating. Stifel Nicolaus maintained the stock with “Buy” rating in Monday, September 18 report. The firm has “Neutral” rating given on Thursday, July 21 by Buckingham Research. The stock of Canadian Pacific Railway Limited (USA) (NYSE:CP) earned “Buy” rating by Buckingham Research on Thursday, April 21.

Seres Therapeutics Incorporated (NASDAQ:MCRB) had an increase of 0.42% in short interest. MCRB’s SI was 2.87M shares in October as released by FINRA. Its up 0.42% from 2.85M shares previously. With 121,200 avg volume, 24 days are for Seres Therapeutics Incorporated (NASDAQ:MCRB)’s short sellers to cover MCRB’s short positions. The SI to Seres Therapeutics Incorporated’s float is 16.38%. About 24,852 shares traded. Seres Therapeutics Inc (NASDAQ:MCRB) has declined 64.58% since October 12, 2016 and is downtrending. It has underperformed by 81.28% the S&P500.

Analysts await Canadian Pacific Railway Limited (USA) (NYSE:CP) to report earnings on October, 18. They expect $2.38 earnings per share, up 13.88% or $0.29 from last year’s $2.09 per share. CP’s profit will be $352.58 million for 17.91 P/E if the $2.38 EPS becomes a reality. After $2.06 actual earnings per share reported by Canadian Pacific Railway Limited (USA) for the previous quarter, Wall Street now forecasts 15.53% EPS growth.

About 188,197 shares traded. Canadian Pacific Railway Limited (USA) (NYSE:CP) has risen 21.39% since October 12, 2016 and is uptrending. It has outperformed by 4.69% the S&P500.

Canadian Pacific Railway Limited, together with its subsidiaries, owns and operates a transcontinental freight railway in Canada and the United States. The company has market cap of $25.26 billion. The Firm operates through rail transportation segment. It has a 19.06 P/E ratio. The Company’s transports bulk commodities, merchandise freight, and intermodal traffic over a network of approximately 12,400 miles.

Among 8 analysts covering Seres Therapeutics Inc (NASDAQ:MCRB), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Seres Therapeutics Inc had 19 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity with “Buy” on Monday, June 12. The stock has “Buy” rating by Canaccord Genuity on Tuesday, August 25. The firm has “Buy” rating by H.C. Wainwright given on Friday, August 4. The firm has “Buy” rating given on Friday, July 29 by H.C. Wainwright. On Wednesday, August 30 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Leerink Swann initiated Seres Therapeutics Inc (NASDAQ:MCRB) rating on Tuesday, July 21. Leerink Swann has “Outperform” rating and $60 target. Bank of America upgraded Seres Therapeutics Inc (NASDAQ:MCRB) on Thursday, October 22 to “Buy” rating. The firm earned “Neutral” rating on Tuesday, July 21 by Bank of America. FBR Capital maintained it with “Outperform” rating and $23 target in Friday, August 12 report. The company was initiated on Tuesday, July 21 by Goldman Sachs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By :